Immunic, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis Comprising DHODH Inhibitors," covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium (IMU-838) and other salt as well as free acid forms for the treatment of relapsing multiple sclerosis (RMS). The claims are expected to provide protection into 2041, unless extended further. Vidofludimus calcium is covered by several layers of granted patents in the United States, Europe and other jurisdictions around the world.

These patents are directed towards composition-of-matter for salt forms of vidoflud Maximus calcium, including the specific salt form used in Immunic's clinical trials, as well as the dose strength used in clinical trials for the treatment of RMS, as reported in this announcement. In the United States, these patents provide protection into 2041, until extended further. In the United States, These patents provide protection into 2041.

In addition, pending applications are directed towards composition-of -matter of a specific polymorph of vidofludius calcium and a related method of production of the clinical material; the dosing regimens including those used in clinical trials for thetreatment of MS; as well as the use of vidofludus calcium and other salt as well asfree acid forms for treating neurodegenerative diseases. If granted, these applications could provide protection up to 2044, unless extended further. Vidofludimus calcium is not yet licensed or approved in any country.